Trial Profile

A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of Investigational Agents in Combination With Standard of Care Treatments as the Second-Line Treatment of Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 03 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary) ; Patritumab Deruxtecan (Primary) ; Ramucirumab (Primary) ; Sacituzumab Tirumotecan (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Adverse reactions; Therapeutic Use
Acronyms Keymaker-U06
Sponsors Merck Sharp & Dohme

23 Jan 2026 Planned End Date changed from 27 Oct 2028 to 8 Oct 2030.
15 Dec 2025 Number of treatment arms increased from 2 to 3 by the addition of Experimental: HER3-DXd (Patritumab-Deruxtecan) + Ramucirumab arm.
15 Dec 2025 Planned number of patients changed from 90 to 210.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com